Extending Therapy Options in Treating Lipid DisordersA Clinical Review of Cerivastatin, a Novel HMG-CoA Reductase Inhibitor

被引：0

作者：

Evan A. Stein

机构：

[1] Medical Research Laboratories,

来源：

Drugs | 1998年 / 56卷

关键词：

Adis International Limited; Pravastatin; Lovastatin; Fluvastatin; Cerivastatin;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Cerivastatin is a third generation pure enantiomeric HMG-CoA reductase inhibitor. It reduces low density lipoprotein (LDL)-cholesterol by 22 to 44% at doses of 0.1 to 0.8 mg/day The drug has been extensively evaluated for more than 5 years in clinical trials and is currently marketed in a number of countries at doses of 0.1 to 0.3 mg/day.

引用

页码：25 / 31

页数：6

共 28 条

[21] A comparison of continuous combined hormone replacement therapy, HMG-CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women
Ozsener, S
Sendag, F
Koc, T
Terek, MC
Oztekin, K
Bilgin, O
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2001, 27 (06) : 353 - 358
[22] HMG-CoA Reductase Inhibitor (Statin) Therapy and Coronary Atherosclerosis in Japanese Subjects Role of High-Density Lipoprotein Cholesterol
Tani, Shigemasa
Nagao, Ken
Hirayama, Atsushi
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2011, 11 (06) : 411 - 417
[23] Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by down-regulation of cellular signaling and the inhibition of PAI-1 promoter activity
Swiatkowska, M
Pawlowska, Z
Szemraj, J
Drzewoski, J
Watala, C
Cierniewski, CS
JAPANESE JOURNAL OF PHARMACOLOGY, 2002, 90 (04) : 337 - 344
[24] Construction of a novel expression vector in Pseudonocardia autotrophica and its application to efficient biotransformation of compactin to pravastatin, a specific HMG-CoA reductase inhibitor
Fujii, Yoshikazu
Norihisa, Koji
Fujii, Tadashi
Aritoku, Yasuhide
Kagawa, Yusuke
Sallam, Khalid Ibrahim
Johdo, Osamu
Arisawa, Akira
Tamura, Tomohiro
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 404 (01) : 511 - 516
[25] Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia
Salazar, LA
Hirata, MH
Quintao, ECR
Hirata, RDC
JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2000, 14 (03) : 125 - 131
[26] Hypolipidemic and Antioxidant Activities of 4,5,6,7-Tetrahydropravastatin Sodium as a Novel HMG-CoA Reductase Inhibitor in High-Fat Diet Rats
Li, Jing
Guan, Su
Zhang, Lei
LATIN AMERICAN JOURNAL OF PHARMACY, 2016, 35 (06): : 1297 - 1303
[27] A novel combination therapy targets sonic hedgehog signaling by the dual inhibition of HMG-CoA reductase and HSP90 in rats with non-alcoholic steatohepatitis
Mohammed, Osama A.
Youssef, Mahmoud E.
Doghish, Ahmed S.
Hamad, Rabab S.
Abdel-Reheim, Mustafa Ahmed
Alghamdi, Mushabab
Alamri, Mohannad Mohammad S.
Alfaifi, Jaber
Adam, Masoud I. E.
Alharthi, Muffarah Hamid
Alhalafi, Abdullah Hassan
Bahashwan, Emad
Rezigalla, Assad Ali
Binafif, Daad Fuad
Abdel-Ghany, Sameh
Attia, Mohammed A.
Elmorsy, Elsayed A.
AL-Noshokaty, Tohada M.
Fikry, Heba
Saleh, Lobna A.
Saber, Sameh
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 198
[28] Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: A novel approach in developing effective chemopreventive regimens
Swamy, MV
Cooma, I
Reddy, BS
Rao, CV
INTERNATIONAL JOURNAL OF ONCOLOGY, 2002, 20 (04) : 753 - 759

← 1 2 3 →